ArticleEuropean journal of clinical nutrition2025
Semaglutide-induced Wernicke encephalopathy: a comprehensive analysis.
Article in European journal of clinical nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case-Based Evidence.Obesity (Silver Spring, Md.) · 2026Pooled it
- Adverse events associated with drug-related thiamine deficiency: A pharmacovigilance study.JPEN. Journal of parenteral and enteral nutrition · 2026Article
- Micronutrient Deficiencies in the Era of Second-Generation Incretin-Based Therapies for Obesity.Nutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although GLP-1 receptors analogues (RAs) benefits-risks profile has been largely documented in diabetes, higher dosages recently approved in obesity still require further assessment. We describe here the case of a 49-year-old female patient treated with semaglutide for obesity, who presented with Wernicke encephalopathy in a context of iterative vomiting and reduced food intake. Eighteen other cases of Wernicke encephalopathy were reported in literature and in the WHO global safety database (VigiBase). A context of nausea/vomiting or reduced food intake is described in 68% of cases, with weight loss ranging from -3.5 to -13.3 kg/month over 3 to 6 months. Disproportionality analysis in VigiBase showed that Wernicke encephalopathy was disproportionately reported with semaglutide, tirzepatide and the whole GLP-1RAs group. Altogether, this comprehensive analysis supports a safety signal regarding the risk of Wernicke encephalopathy with GLP-1RAs, which requires a prompt assessment, accounting for the growing use of these drugs.
Indexed as
Identifiers
40908328What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.